Tsu‐Han Lin

917 total citations
20 papers, 751 citations indexed

About

Tsu‐Han Lin is a scholar working on Oncology, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Tsu‐Han Lin has authored 20 papers receiving a total of 751 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 6 papers in Molecular Biology and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Tsu‐Han Lin's work include Drug Transport and Resistance Mechanisms (7 papers), Drug Solubulity and Delivery Systems (3 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Tsu‐Han Lin is often cited by papers focused on Drug Transport and Resistance Mechanisms (7 papers), Drug Solubulity and Delivery Systems (3 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Tsu‐Han Lin collaborates with scholars based in United States, Switzerland and Japan. Tsu‐Han Lin's co-authors include William P. Dole, R. Sarangapani, Adele Noè, Gary M. Ksander, Monica Ligueros‐Saylan, Suliman Al‐Fayoumi, Jessie Gu, Arco Y. Jeng, Handan He and Tycho Heimbach and has published in prestigious journals such as Journal of Hepatology, Biochemical Pharmacology and Pharmaceutical Research.

In The Last Decade

Tsu‐Han Lin

20 papers receiving 739 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tsu‐Han Lin United States	13	371	149	130	121	103	20	751
Jan Jaap van Lier United States	18	162 0.4×	318 2.1×	123 0.9×	340 2.8×	64 0.6×	38	1.0k
A. K. Pedersen Denmark	17	543 1.5×	152 1.0×	55 0.4×	60 0.5×	72 0.7×	38	1.1k
J. Wagner Switzerland	8	311 0.8×	201 1.3×	51 0.4×	166 1.4×	26 0.3×	13	744
B. Kaufmann Germany	14	247 0.7×	86 0.6×	63 0.5×	56 0.5×	72 0.7×	29	650
Katrijn Bogman Switzerland	10	71 0.2×	192 1.3×	317 2.4×	92 0.8×	120 1.2×	18	732
Christopher M. Waldmann United States	11	301 0.8×	162 1.1×	90 0.7×	93 0.8×	36 0.3×	19	796
Uwe J. Ries Germany	11	558 1.5×	290 1.9×	71 0.5×	82 0.7×	27 0.3×	17	1.2k
Stefan Blech Germany	6	450 1.2×	120 0.8×	99 0.8×	163 1.3×	23 0.2×	8	771
Hannah Lu United States	8	204 0.5×	62 0.4×	75 0.6×	107 0.9×	38 0.4×	9	441
Toshimi Kanbe Japan	18	174 0.5×	249 1.7×	59 0.5×	52 0.4×	72 0.7×	38	1.0k

Countries citing papers authored by Tsu‐Han Lin

Since Specialization

Citations

This map shows the geographic impact of Tsu‐Han Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tsu‐Han Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tsu‐Han Lin more than expected).

Fields of papers citing papers by Tsu‐Han Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tsu‐Han Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tsu‐Han Lin. The network helps show where Tsu‐Han Lin may publish in the future.

Co-authorship network of co-authors of Tsu‐Han Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Tsu‐Han Lin. A scholar is included among the top collaborators of Tsu‐Han Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tsu‐Han Lin. Tsu‐Han Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Einolf, Heidi J., Surya Ayalasomayajula, Tsu‐Han Lin, et al.. (2017). Evaluation of Drug-Drug Interaction Potential Between Sacubitril/Valsartan (LCZ696) and Statins Using a Physiologically Based Pharmacokinetic Model. Journal of Pharmaceutical Sciences. 106(5). 1439–1451. 18 indexed citations

Kulmatycki, Kenneth, Thomas Langenickel, Dik Ng, et al.. (2017). Pharmacokinetics and safety of sacubitril/valsartan (LCZ696) in patients with mild and moderate hepatic impairment. International Journal of Clinical Pharmacology and Therapeutics. 55(9). 728–739. 8 indexed citations

Pal, Parasar, Tsu‐Han Lin, Tapan Majumdar, et al.. (2015). Effect of Renal Impairment on the Pharmacokinetics of Pradigastat, a Novel Diacylglycerol Acyltransferase1 (DGAT1) Inhibitor. Clinical Pharmacokinetics. 54(7). 751–760. 3 indexed citations

Li, Li, Julie Boisclair, Wenkui Li, et al.. (2015). Osilodrostat (LCI699), a potent 11β-hydroxylase inhibitor, administered in combination with the multireceptor-targeted somatostatin analog pasireotide: A 13-week study in rats. Toxicology and Applied Pharmacology. 286(3). 224–233. 14 indexed citations

Hirano, Masaru, Parasar Pal, Tsu‐Han Lin, et al.. (2015). Effect of Hepatic Impairment on the Pharmacokinetics of Pradigastat, a Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor. Clinical Pharmacokinetics. 54(7). 761–770. 6 indexed citations

Zhang, Hefei, Binfeng Xia, Jennifer Sheng, et al.. (2014). Application of Physiologically Based Absorption Modeling to Formulation Development of a Low Solubility, Low Permeability Weak Base: Mechanistic Investigation of Food Effect. AAPS PharmSciTech. 15(2). 400–406. 29 indexed citations

Xia, Binfeng, Tycho Heimbach, Tsu‐Han Lin, et al.. (2013). Utility of Physiologically Based Modeling and Preclinical In Vitro/In Vivo Data to Mitigate Positive Food Effect in a BCS Class 2 Compound. AAPS PharmSciTech. 14(3). 1255–1266. 20 indexed citations

Heimbach, Tycho, Binfeng Xia, Tsu‐Han Lin, & Handan He. (2012). Case Studies for Practical Food Effect Assessments across BCS/BDDCS Class Compounds using In Silico, In Vitro, and Preclinical In Vivo Data. The AAPS Journal. 15(1). 143–158. 46 indexed citations

Xia, Binfeng, Tycho Heimbach, Tsu‐Han Lin, et al.. (2012). Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions. Cancer Chemotherapy and Pharmacology. 69(6). 1567–1582. 21 indexed citations

10.

Lin, Tsu‐Han, et al.. (2012). Unsymmetrical Squaraines Incorporating Cabazole as a Donor for Dye‐Sensitized Solar Cells. Journal of the Chinese Chemical Society. 59(10). 1337–1344. 2 indexed citations

11.

Xia, Binfeng, Tycho Heimbach, Handan He, & Tsu‐Han Lin. (2012). Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability. Biopharmaceutics & Drug Disposition. 33(9). 536–549. 33 indexed citations

12.

Gu, Jessie, Adele Noè, Priya Chandra, et al.. (2009). Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual‐Acting Angiotensin Receptor—Neprilysin Inhibitor (ARNi). The Journal of Clinical Pharmacology. 50(4). 401–414. 406 indexed citations

13.

Yin, Ophelia, Neil J. Gallagher, Chiaki Tanaka, et al.. (2009). Effects of hepatic impairment on the pharmacokinetics of nilotinib: An open-label, single-dose, parallel-group study. Clinical Therapeutics. 31. 2459–2469. 29 indexed citations

14.

Grubbs, Clinton J., Donald L. Hill, Kirby I. Bland, et al.. (2003). 9cUAB30, an RXR specific retinoid, and/or tamoxifen in the prevention of methylnitrosourea-induced mammary cancers. Cancer Letters. 201(1). 17–24. 37 indexed citations

15.

Lin, Tsu‐Han, Tina S. Rogers, Donald L. Hill, et al.. (1996). Murine Toxicology and Pharmacology of UAB-8, a Conformationally Constrained Analog of Retinoic Acid. Toxicology and Applied Pharmacology. 139(2). 310–316. 2 indexed citations

16.

Ichikawa, Makoto, Tsu‐Han Lin, Seiji Miyauchi, et al.. (1992). ‘Albumin-mediated transport phenomenon’ observed for ligands with high membrane permeability. Journal of Hepatology. 16(1-2). 38–49. 37 indexed citations

17.

Lin, Jiunn H., Tsu‐Han Lin, & Haiyung Cheng. (1992). Uptake and Stereoselective Binding of the Enantiomers of MK-927, a Potent Carbonic Anhydrase Inhibitor, by Human Erythrocytes in Vitro. Pharmaceutical Research. 9(3). 339–344. 12 indexed citations

18.

Lin, Tsu‐Han, Yasufumi Sawada, Yuichi Sugiyama, Tatsuji Iga, & Manabu Hanano. (1987). Inhibition of blood-brain barrier permeability to dl-propranolol by serum from acute renal failure rats. Biochemical Pharmacology. 36(20). 3425–3431. 6 indexed citations

19.

Lin, Tsu‐Han, Yasufumi Sawada, Yuichi Sugiyama, Tatsuji Iga, & Manabu Hanano. (1987). Effects of albumin and .ALPHA.1-acid glycoprotein on the transport of imipramine and desipramine through the blood-brain barrier in rats.. Chemical and Pharmaceutical Bulletin. 35(1). 294–301. 15 indexed citations

20.

Lin, Tsu‐Han, Yasufumi Sawada, Yuichi Sugiyama, Tatsuji Iga, & Manabu Hanano. (1985). Effect of phenobarbitone on the distribution and elimination of imipramine in rats. Journal of Pharmacy and Pharmacology. 37(10). 735–738. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact